Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;79(2):511-530.
doi: 10.3233/JAD-200747.

APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid

Miles Berger  1   2   3 , Mary Cooter  1 , Alexander S Roesler  1 , Stacey Chung  1 , John Park  1 , Jennifer L Modliszewski  4 , Keith W VanDusen  1 , J Will Thompson  4 , Arthur Moseley  4 , Michael J Devinney  1 , Shayan Smani  1   5 , Ashley Hall  1 , Victor Cai  1   5 , Jeffrey N Browndyke  2   3   6 , Michael W Lutz  7 , David L Corcoran  4 ; and Alzheimer’s Disease Neuroimaging Initiative
Affiliations

APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid

Miles Berger et al. J Alzheimers Dis. 2021.

Erratum in

  • Erratum to: APOE4 Copy Number-Dependent Proteomic Changes in the Cerebrospinal Fluid.
    Berger M, Cooter M, Roesler AS, Chunga S, Park J, Modliszewski JL, VanDusen KW, Thompson JW, Moseley A, Devinney MJ, Smani S, Hall A, Cai V, Browndyke JN, Lutz MW, Corcoran DL; and Alzheimer’s Disease Neuroimaging Initiative. Berger M, et al. J Alzheimers Dis. 2022;90(3):1339-1340. doi: 10.3233/JAD-229018. J Alzheimers Dis. 2022. PMID: 36373324 Free PMC article. No abstract available.

Abstract

Background: APOE4 has been hypothesized to increase Alzheimer's disease risk by increasing neuroinflammation, though the specific neuroinflammatory pathways involved are unclear.

Objective: Characterize cerebrospinal fluid (CSF) proteomic changes related to APOE4 copy number.

Methods: We analyzed targeted proteomic data from ADNI CSF samples using a linear regression model adjusting for age, sex, and APOE4 copy number, and additional linear models also adjusting for AD clinical status or for CSF Aβ, tau, or p-tau levels. False discovery rate was used to correct for multiple comparisons correction.

Results: Increasing APOE4 copy number was associated with a significant decrease in a CRP peptide level across all five models (q < 0.05 for each), and with significant increases in ALDOA, CH3L1 (YKL-40), and FABPH peptide levels (q < 0.05 for each) except when controlling for AD clinical status or neurodegeneration biomarkers (i.e., CSF tau or p-tau). In all models except the one controlling for CSF Aβ levels, though not statistically significant, there was a consistent inverse direction of association between APOE4 copy number and the levels of all 24 peptides from all 8 different complement proteins measured. The odds of this happening by chance for 24 unrelated peptides would be less than 1 in 16 million.

Conclusion: Increasing APOE4 copy number was associated with decreased CSF CRP levels across all models, and increased CSF ALDOA, CH3L1, and FABH levels when controlling for CSF Aβ levels. Increased APOE4 copy number may also be associated with decreased CSF complement pathway protein levels, a hypothesis for investigation in future studies.

Keywords: Alzheimer disease; C-reactive protein; apolipoprotein E4; biomarker; cerebrospinal fluid; complement activation; mass spectrometry; neurogenic inflammation.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/20-0747r2).

Figures

Fig. 1
Fig. 1
Volcano Plot of CSF Protein/Peptide Expression by APOE genotype, for the top 20 proteins and the complement cascade proteins in model 1 (A), and for the top 20 proteins and the complement cascade proteins in model 2 (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G, Roses A, Haines J, Pericak-Vance M (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 261, 921–923. - PubMed
    1. Neu SC, Pa J, Kukull W, Beekly D, Kuzma A, Gangadharan P, Wang LS, Romero K, Arneric SP, Redolfi A, Orlandi D, Frisoni GB, Au R, Devine S, Auerbach S, Espinosa A, Boada M, Ruiz A, Johnson SC, Koscik R, Wang JJ, Hsu WC, Chen YL, Toga AW (2017) Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-analysis. JAMA Neurol 74, 1178–1189. - PMC - PubMed
    1. Loy CT, Schofield PR, Turner AM, Kwok JBJ (2014) Genetics of dementia. Lancet 383, 828–840. - PubMed
    1. Holtzman DM, Herz J, Bu G (2012) Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2, a006312. - PMC - PubMed
    1. Michaelson DM (2014) APOE ɛ4: The most prevalent yet understudied risk factor for Alzheimer’s disease. Alzheimers Dement 10, 861–868. - PubMed

Publication types